Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 10.11.2025 1 AJR Am J Roentgenol 1 Am J Clin Oncol 3 Ann Surg Oncol 2 Arch Bronconeumol 2 BMC Cancer 1 BMJ 1 Cancer Chemother Pharmacol 2 Cancer Epidemiol Biomarkers Prev 4 Cancer Sci 7 Clin Lung Cancer 3 Eur J Cancer 1 Eur Respir J 5 Int J Cancer 1 J Cancer Res Clin Oncol 2 J Clin Invest 1 J Natl Cancer Inst 4 J Thorac Cardiovasc Surg 1 J Thorac Oncol 1 Lancet 7 Lung Cancer 1 Mol Cancer Ther 1 Oncogene 1 PLoS One 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. MAI M, Kim H, Omar A, Abraham J, et al
   Image-Guided Thermal Ablation in Patients With Locally Recurrent Non-Small Cell Lung Cancer After Stereotactic-Beam Radiation Therapy.
   AJR Am J Roentgenol. 2025 Nov 5. doi: 10.2214/AJR.25.33831.
   PubMed        
   
   

   
   Am J Clin Oncol

2. FRIEDES C, Iocolano M, Yegya-Raman N, Kucharczuk JC, et al
   Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy.
   Am J Clin Oncol. 2025 Nov 10. doi: 10.1097/COC.0000000000001260.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. DENSON KL, Broad S, Naeem W, Geissen NM, et al
   ASO Author Reflections: Skeletal Muscle Gauge as a Prognosticator of Survival in Resected Early-Stage Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Nov 5. doi: 10.1245/s10434-025-18683.
   PubMed        
   
   
4. MIZOTA K, Kinoshita F, Giacomo B, Tokunaga T, et al
   The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
   Ann Surg Oncol. 2025 Nov 1. doi: 10.1245/s10434-025-18661.
   PubMed         Abstract available
   
   
5. PERON J, Essadi I, Rousset P, Villeneuve L, et al
   Assessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients.
   Ann Surg Oncol. 2025;32:9731-9740.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

6. DE-TORRES JP, Wilson DO, Wisnivesky JP, Salvatore MM, et al
   Chronic Respiratory Diseases and Lung Cancer Risk.
   Arch Bronconeumol. 2025 Oct 25:S0300-2896(25)00383.
   PubMed         Abstract available
   
   
7. PARDESSUS A, Chalela R, Sanchez-Font A
   Peripheral Lung Cancer Diagnosis with New-Generation Convex-Probe Endobronchial Ultrasound Bronchoscope: A Case Report.
   Arch Bronconeumol. 2025 Oct 11:S0300-2896(25)00357.
   PubMed        
   
   

   
   BMC Cancer

8. REYES-REYES E, Cuetara-Lugo E, Herrera-Isidron JA, Perez-Benitez M, et al
   Polymorphisms in DNA repair related genes as risk factors for lung cancer in Cuban population: a case control study.
   BMC Cancer. 2025;25:1717.
   PubMed         Abstract available
   
   
9. FU YL, Tang ZY, Zhu YY, Liu QW, et al
   Clinical significance and minimal clinically important differences for the survival outcomes in randomized clinical trials of lung cancer.
   BMC Cancer. 2025;25:1712.
   PubMed         Abstract available
   
   

   
   BMJ

10. 
    Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial.
    BMJ. 2025;391:r2300.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

11. TER HEINE R, van den Bosch BJC, van Geel RM, van Geffen WH, et al
    Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity.
    Cancer Chemother Pharmacol. 2025;95:105.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

12. NASH SH, Loeffler BT, Verhage E, Sorensen J, et al
    Comorbidities among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results-Medicare Study.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1914-1923.
    PubMed         Abstract available
    
    
13. DENNISON JB, Gendarme S, Kettner NM, Godoy MCB, et al
    The LEAP Study: A Multicenter Biospecimen and Imaging Resource for Lung Cancer Screening.
    Cancer Epidemiol Biomarkers Prev. 2025 Nov 5. doi: 10.1158/1055-9965.EPI-25-1022
    PubMed         Abstract available
    
    

    
    Cancer Sci

14. KIWAKI T, Tanaka H, Kawaguchi M, Umekita Y, et al
    Low-Density Lipoprotein Receptor-Related Protein 11 Promotes Proliferation in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:3090-3101.
    PubMed         Abstract available
    
    
15. WEI T, Cao W, Zhang Q, Wu E, et al
    Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers.
    Cancer Sci. 2025;116:3185-3195.
    PubMed         Abstract available
    
    
16. KITAZONO S, Ono A, Kawamura T, Hataji O, et al
    Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.
    Cancer Sci. 2025;116:3139-3148.
    PubMed         Abstract available
    
    
17. CHEN J, Pan Y, Zhang B, Li M, et al
    Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases.
    Cancer Sci. 2025;116:3125-3138.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

18. LEE JW, Lee SW, Kang H, Lee YH, et al
    Association Between Lung Volume Reduction and Symptomatic Radiation Pneumonitis in Lung Cancer Patients Undergoing Definitive Concurrent Chemoradiotherapy.
    Clin Lung Cancer. 2025 Nov 5:S1525-7304(25)00266.
    PubMed         Abstract available
    
    
19. HETTINGER GCN, Long Q, Parikh RB
    Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data.
    Clin Lung Cancer. 2025 Sep 26:S1525-7304(25)00236.
    PubMed         Abstract available
    
    
20. PHAM D, Thakur N, Park JA, Nie W, et al
    Computer Assisted Nodule Analysis and Risk Yield Outcomes May be Associated with Recurrence after Stereotactic Body Radiation Therapy in Clinical Stage I Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2025 Oct 10:S1525-7304(25)00265.
    PubMed         Abstract available
    
    
21. TAKEMURA C, Yoshida T, Yoshida Y, Higashiyama RI, et al
    Genomic Profiles as Predictors of Occult Lymph Node Metastasis and Clinical Outcomes in Early-Stage Clinical N0 Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Oct 10:S1525-7304(25)00242.
    PubMed         Abstract available
    
    
22. KATANO A, Miki Y, Minamitani M, Sawayanagi S, et al
    Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer in Patients Aged 80 Years and Older: A Single-Center Retrospective Cohort Study of Octogenarians and Nonagenarians.
    Clin Lung Cancer. 2025 Oct 13:S1525-7304(25)00268.
    PubMed         Abstract available
    
    
23. KOJIMA S, Inoue Y, Karayama M, Hashimoto D, et al
    Biological Aging and Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Receiving Systemic Therapy.
    Clin Lung Cancer. 2025 Oct 13:S1525-7304(25)00267.
    PubMed         Abstract available
    
    
24. AZUMA M, Nguyen A, Tompkins AK, Chin K, et al
    Lost to Follow-up: Social Determinants and Patient Perceptions in Lung Cancer Screening Adherence.
    Clin Lung Cancer. 2025 Oct 10:S1525-7304(25)00262.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

25. COHEN GL, Coetzee C, Walton CA, Reig Torras O, et al
    Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.
    Eur J Cancer. 2025;230:115709.
    PubMed         Abstract available
    
    
26. ZHANG R, Li H, Ding L, Liu H, et al
    Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study.
    Eur J Cancer. 2025;230:116056.
    PubMed         Abstract available
    
    
27. MENIS J, Greiller L, Demontrond P, Monnet I, et al
    EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
    Eur J Cancer. 2025;231:116059.
    PubMed         Abstract available
    
    

    
    Eur Respir J

28. LIU HJ, Diesler R, Chami J, Wu B, et al
    Modulation of infiltrating CD206(+) macrophages restricts progression of pulmonary lymphangioleiomyomatosis.
    Eur Respir J. 2025;66:2500084.
    PubMed         Abstract available
    
    

    
    Int J Cancer

29. ZENG C, Tan Y, Jiao Z, Hu S, et al
    A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.
    Int J Cancer. 2026;158:172-181.
    PubMed         Abstract available
    
    
30. WU J, Mo A, Zhuang W, Chen R, et al
    Distinctive clinical and radiological characteristics of persistent super-multiple ground-glass pulmonary nodules.
    Int J Cancer. 2026;158:60-68.
    PubMed         Abstract available
    
    
31. LIANG XL, Su YD, Fu YB, Yu Y, et al
    Efficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching.
    Int J Cancer. 2026;158:232-242.
    PubMed         Abstract available
    
    
32. YU S, Li H, Lu H, Huang Z, et al
    Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.
    Int J Cancer. 2025 Nov 6. doi: 10.1002/ijc.70224.
    PubMed         Abstract available
    
    
33. MO H, Zhang Y, Tian Z, Yue P, et al
    Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non-small cell lung cancer: A single-center retrospective
    Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70238.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

34. TAUGNER J, Stamer S, Hofstetter K, Eze C, et al
    Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy.
    J Cancer Res Clin Oncol. 2025;151:313.
    PubMed         Abstract available
    
    

    
    J Clin Invest

35. HAJI S, Ogawa Y
    TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases.
    J Clin Invest. 2025;135:e198802.
    PubMed         Abstract available
    
    
36. LIU B, Dai Y, Wang Z, Song J, et al
    TET3 is a common epigenetic immunomodulator of pathogenic macrophages.
    J Clin Invest. 2025;135:e194879.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

37. RAGER JB, Cao P, Hayward RA, Meza R, et al
    Personalizing lung cancer screening recommendations for heterogenous populations: a microsimulation study.
    J Natl Cancer Inst. 2025 Nov 3:djaf316. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

38. KOLIAKOS E, Overbeek C, Guay J, Zaouter C, et al
    Intercostal cryoanalgesia for acute pain after video-assisted thoracic surgery lung resection: A randomized controlled preliminary trial.
    J Thorac Cardiovasc Surg. 2025;170:1242-1251.
    PubMed         Abstract available
    
    
39. YANG F, Guo J, Yang Z, Li Z, et al
    The clinicopathological characteristics and prognosis of mucin-laden nonmucinous lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2025;170:1254-1268.
    PubMed         Abstract available
    
    
40. FUKAMI T, Tsutani Y
    Reply: Understanding Deauville score in stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2025 Nov 4:S0022-5223(25)00861.
    PubMed        
    
    
41. ORTIZ BA, Roden AC, Wigle DA, Tapias LF, et al
    Reply: Intraoperative knowledge is power-the case for better understanding frozen section pathology in lung cancer.
    J Thorac Cardiovasc Surg. 2025 Nov 4:S0022-5223(25)00874.
    PubMed        
    
    

    
    J Thorac Oncol

42. CARBONE DP, Hirsch FR, Osarogiagbon RU, Nishimura KK, et al
    Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic O
    J Thorac Oncol. 2025 Nov 1:S1556-0864(25)02853.
    PubMed        
    
    

    
    Lancet

43. AERTS JG, Dammeijer F
    Progress in outcomes for patients with metastatic squamous non-small-cell lung cancer.
    Lancet. 2025;406:2034-2035.
    PubMed        
    
    

    
    Lung Cancer

44. CHEN ACC, Mok FST, Wong WKY, Lam BHW, et al
    Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.
    Lung Cancer. 2025;210:108808.
    PubMed         Abstract available
    
    
45. ROLFO C, Gerber DE, Kotecha R, Ward JP, et al
    The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.
    Lung Cancer. 2025;210:108802.
    PubMed         Abstract available
    
    
46. BAILEY HR, Tam HZ, Vulkan D, Brunelli A, et al
    Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy.
    Lung Cancer. 2025;210:108816.
    PubMed         Abstract available
    
    
47. BORGHETTI P, D'Angelillo R, Facheris G, Borghesi A, et al
    Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO).
    Lung Cancer. 2025;210:108807.
    PubMed         Abstract available
    
    
48. DESAI RK, Zhou EJ, Chan KKW
    Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer.
    Lung Cancer. 2025;210:108812.
    PubMed         Abstract available
    
    
49. RICKETTS W, Sandsund C, Merchant Z, Franks K, et al
    Delivering equitable access to prehabilitation services to optimise outcomes for patients with lung cancer - Best practice recommendations from a UK roundtable event.
    Lung Cancer. 2025;210:108805.
    PubMed         Abstract available
    
    
50. JIE GL, Zhong JX, Wang JZ, Cao ZQ, et al
    Plasma proteomics profiling identifies predictive biomarkers for immunotherapy response in small-cell lung cancer.
    Lung Cancer. 2025;210:108811.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

51. SUMII M, Masuda T, Shimoji K, Yamaguchi K, et al
    Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2025 Nov 6. doi: 10.1158/1535-7163.MCT-24-0890.
    PubMed         Abstract available
    
    

    
    Oncogene

52. ZHANG W, Li J, Zhao J, Lu D, et al
    Targeting ZNRF2-mediated SLC3A2 plasma membrane translocation enhances ferroptosis in lung adenocarcinoma.
    Oncogene. 2025;44:4339-4351.
    PubMed         Abstract available
    
    

    
    PLoS One

53. XUE Y, Wang Y, Huang T, Dong Y, et al
    Construction and validation of an anoikis-related prognostic model for lung adenocarcinoma based on bulk and single-cell transcriptomic data.
    PLoS One. 2025;20:e0335788.
    PubMed         Abstract available
    
    

    
    Semin Oncol

54. GANATRA N, Thompson J, Desai R, Doshi J, et al
    Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Semin Oncol. 2025;52:152431.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.